US20080241106A1 - Method for Preventing and Treating Diabetes Using Neurturin - Google Patents

Method for Preventing and Treating Diabetes Using Neurturin Download PDF

Info

Publication number
US20080241106A1
US20080241106A1 US10/580,601 US58060104A US2008241106A1 US 20080241106 A1 US20080241106 A1 US 20080241106A1 US 58060104 A US58060104 A US 58060104A US 2008241106 A1 US2008241106 A1 US 2008241106A1
Authority
US
United States
Prior art keywords
cells
neurturin
pancreatic
insulin
product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/580,601
Other languages
English (en)
Inventor
Matthias Austen
Ulrike Burk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Develogen AG
Original Assignee
Develogen AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Develogen AG filed Critical Develogen AG
Assigned to DEVELOGEN AKTIENGESELLSCHAFT reassignment DEVELOGEN AKTIENGESELLSCHAFT ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: AUSTEN, MATTHIAS, BURK, ULRIKE
Publication of US20080241106A1 publication Critical patent/US20080241106A1/en
Priority to US13/028,181 priority Critical patent/US8399408B2/en
Priority to US13/769,011 priority patent/US8772233B2/en
Priority to US14/287,863 priority patent/US20140274897A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/507—Pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/13—Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells

Definitions

  • the present invention relates generally to methods for preventing and/or treating pancreatic disorders, particularly those related to diabetes, by administering a neurturin product.
  • the pancreas is an exocrine gland that secretes digestive enzymes directly into the digestive tract as well as an endocrine gland that secretes hormones into the blood stream.
  • the exocrine function is assured by acinar and centroacinar cells that secrete various digestive enzymes via intercalated ducts into the duodenum.
  • the functional unit of the endocrine pancreas is the islet of Langerhans. Islets are scattered throughout the exocrine portion of the pancreas and are composed of four main cell types: alpha-, beta-, delta- and PP-cells (reviewed for example in Kim & Hebrok, 2001, Genes Dev. 15: 111-127).
  • Beta-cells produce insulin, represent the majority of the endocrine cells and form the core of the islets, while alpha-cells secrete glucagon and are located in the periphery. Delta-cells and PP-cells are less numerous and secrete somatostatin and pancreatic polypeptide, respectively. Recently, cells producing the neuropeptide Ghrelin have been found in pancreatic islets (Wierup et al., 2002, Regul Pept. 107:63-9).
  • pancreatic development has been well studied in different species, including chicken, zebrafish, and mice (for a detailed review, see Kim & Hebrok, 2001, supra).
  • the pancreas develops from distinct dorsal and ventral anlagen.
  • Pancreas development requires specification of the pancreas strom along both anterior-posterior and dorsal-ventral axes.
  • a number of transcription factors, that are critical for proper pancreatic development have been identified (see Kim & Hebrok, 2001, supra; Wilson et al., 2003, Mech Dev. 120: 65-80).
  • pancreatic islets of Langerhans originate from differentiating duct cells or other cells with epithelial morphology (Bonner-Weir & Sharma, 2002, J Pathol. 197: 519-526; Gu et al., 2003, Mech Dev. 120: 35-43).
  • Pancreatic beta-cells secrete insulin in response to blood glucose levels. Insulin amongst other hormones plays a key role in the regulation of the fuel metabolism. Insulin leads to the storage of glycogen and triglycerides and to the synthesis of proteins. The entry of glucose into muscles and adipose cells is stimulated by insulin. In patients who suffer from diabetes mellitus type I or LADA (latent autoimmune diabetes in adults (Pozzilli & Di Mario, 2001, Diabetes Care. 8:1460-67) beta-cells are being destroyed due to autoimmune attack. The amount of insulin produced by the remaining pancreatic islet cells is too low, resulting in elevated blood glucose levels (hyperglycemia).
  • beta-cell neogenesis does not appear to change in type II diabetics (Butler et al., 2003 supra), thus causing a reduction in total beta-cell mass over time. Eventually the application of exogenous insulin becomes necessary in type II diabetics.
  • beta-cells are being destroyed by autoimmune attack
  • treatments have been devised which modulate the immune system and may be able to stop or strongly reduce islet destruction (Raz et al., 2001, Lancet 358: 1749-1753; Chatenoud et al., 2003, Nat Rev Immunol. 3: 123-132; Homann et al., Immunity. 2002, 3:403-15).
  • islet destruction due to the relatively slow regeneration of human beta-cells such treatments can only be successful if they are combined with agents that can stimulate beta-cell regeneration.
  • Diabetes is a very disabling disease, because today's common anti-diabetic drugs do not control blood sugar levels well enough to completely prevent the occurrence of high and low blood sugar levels. Out of range blood sugar levels are toxic and cause long-term complications like for example renopathy, retinopathy, neuropathy and peripheral vascular disease. There is also a host of related conditions, such as obesity, hypertension, heart disease and hyperlipidemia, for which persons with diabetes are substantially at risk.
  • Neurotrophic factors are growth factors that regulate the survival and maintain the phenotypic differentiation of certain nerve and/or glial cell populations (Varon et al., 1978, Ann. Rev. Neurosience 1: 327-361; Thoenen et al., Science, 229:238-242, 1985).
  • Nerve growth factor (NGF) was the first neurotrophic factor to be identified and characterized (Levi-Montalcini et al., 1951, J. Exp. Zool. 116:321). The second member of this family to be discovered was brain-derived neurotrophic factor (Leibrock et al., 1989, Nature 341:149-152).
  • Glial-derived neurotrophic factor (GDNF)—a neurotrophic factor structurally unrelated to NGF—was discovered during a search for factors crucial to the survival of midbrain dopaminergic neurons, which degenerate in Parkinson's disease (Lin et al., 1993, Science 260:1130-2). Sequence analysis revealed it to be a distant member of the superfamily of transforming growth factor 8 (TGF-beta) factors.
  • TGF-beta transforming growth factor 8
  • TGF-beta-related neurotrophins Another neurotrophic factor that is structurally closely related to GDNF and unrelated to NGF is neurturin (Kotzbauer et al., 1996, Nature 384: 467-470).
  • Neurturin, GDNF and two other related factors (artemin and persephin) define a family of neurotrophic factors referred to as TGF-beta-related neurotrophins.
  • TGF-beta-related neurotrophins These neurotrophic factors promote the survival of various neurons including peripheral autonomic and sensory neurons as well as central motor and dopamine neurons, and have been proposed as therapeutic agents for neurodegenerative diseases (see review by Takahashi, 2001, Cytokine Growth Factor Rev 12(4):361-73; see also, for example, U.S. Pat. No.
  • TGF-beta-related neurotrophins signal through a unique two-receptor complex consisting of a glycosylphosphatidylinositol-linked cell surface molecule, the GDNF family receptor alpha (GFRalpha) and receptor protein tyrosine kinase Ret.
  • GFRalpha glycosylphosphatidylinositol-linked cell surface molecule
  • Ret receptor protein tyrosine kinase Ret.
  • GDNF/RET signalling is crucial for the differentiation of certain non-neuronal tissues.
  • GFRalpha1 and the Ret are both necessary receptor components for ureteric bud outgrowth and subsequent branching in the developing kidney (Cacalano et al., 1998, Neuron 21:53-62; Tang et al., 1998, J Cell Biol. 142 (5):1337-45).
  • Ret, GFRalpha-1 (the GDNF receptor), and GFRalpha-2 (the Neurturin receptor) are expressed by testicular germ cells, while GDNF and Neurturin are expressed by Sertoli cells. Both GDNF and Neurturin stimulate DNA synthesis in spermatogonia.
  • GFRalpha, GFRalpha ligands and co-receptors are expressed in germ cell tumors and thus may act as paracrine factors in spermatogenesis (Viglietto et al., 2000, Int J Oncol. 16(4):689-94).
  • GDNF family ligands also signal through the neural cell adhesion molecule NCAM.
  • NCAM neural cell adhesion molecule
  • GDNF binds with high affinity to the NCAM and GFRalpha1 complex (see review by Sariola & Saarma, 2003, J Cell Sci. 116(Pt 19):3855-62).
  • Signalling via the c-met receptor kinases has also been demonstrated (see Popsueva et al., 2003, J Cell Biol. 161(1):119-29).
  • GDNF/RET signalling is crucial for the differentiation of neuronal and certain non-neuronal tissues
  • a member of family of TGF-beta-related neurotrophins is involved in the regeneration of pancreatic tissue.
  • neurturin stimulates the formation or regeneration of insulin producing pancreatic beta-cells which play an essential role in diabetes.
  • the present invention relates to new methods for stimulating and/or inducing the differentiation of progenitor cells, e.g. stem cells into insulin-producing cells or for promoting the protection, survival and/or regeneration of insulin producing cells using a neurturin product and/or a modulator/effector thereof that influences, particularly increases the expression level or function of a neurturin protein product.
  • progenitor cells e.g. stem cells into insulin-producing cells or for promoting the protection, survival and/or regeneration of insulin producing cells using a neurturin product and/or a modulator/effector thereof that influences, particularly increases the expression level or function of a neurturin protein product.
  • the present invention provides methods for treating patients suffering from a disease caused by, associated with, and/or accompanied by functionally impaired and/or reduced numbers of pancreatic islet cells, particularly insulin producing beta-cells, by administering a therapeutically effective amount of a neurturin product or a compound that influences the neurturin expression level or function.
  • Functional impairment or loss of pancreatic islet cells may be due to e.g. autoimmune attack such as in diabetes type I or LADA, and/or due to cell degeneration such as in progressed diabetes type II.
  • the methods of the present invention may also be used to treat patients at risk to develop degeneration of insulin producing beta-cells to prevent the start or progress of such process.
  • the neurturin product or the effector/modulator thereof may be administered e.g. as a pharmaceutical composition, via implantation of neurturin product expressing cells, and/or via gene therapy.
  • the invention relates to cell preparations comprising neurturin-treated insulin producing cells or neurturin expressing cells.
  • FIG. 1 shows the neurturin dependent induction of the differentiation of insulin producing cells.
  • ES cells Mouse embryonic stem (ES) cells were differentiated to insulin producing cells as described previously (patent application PCT/EP02/04362, published as WO 02/086107, which is incorporated herein by reference).
  • insulin mRNA FIGS. 1A and 1B
  • beta-cell glucose transporter Glut2 mRNA FIGS. 1C and 1D
  • levels were normalized using 18S RNA as control and a cycle number of 36 as reference.
  • the numbers on the vertical line refer to the abundance of the indicated transcripts relative to an abundance for which 36 cycles are necessary for detection.
  • ‘wt ES’ refers to unmodified mouse R1 embryonic stem (ES) cells; ‘Pax4 ES’ refers to R1 mouse embryonic stem (ES) cells stably transfected with a CMV-Pax4 expression construct; ‘insulin expression rel. to delta Ct36’ refers to expression of insulin; ‘Glut2 expression rel. to delta Ct36’ refers to expression of beta-cell glucose transporter; ‘ES’ refers to mouse embryonic stem cells, as described in Example 1; ‘control’ refers to the differentiation protocol as described in Example 2, without any addition of neurturin; ‘EB+NTN’ refers to the differentiation protocol as described in Example 3, with the addition of neurturin to embryoid bodies).
  • FIG. 2 shows the structure of the mouse mDG770 transgenic construct. Shown is the rIP promoter (0.8 kb rat insulin II promoter) as a thin line, the mouse DG770 cDNA (mDG770) as white box, the hybrid-intron structure (hybrid-intron) as grey box and the polyadenylation signal (bgh-polyA) as black box.
  • rIP promoter 0.8 kb rat insulin II promoter
  • mDG770 mouse DG770 cDNA
  • hybrid-intron structure hybrid-intron structure
  • bgh-polyA polyadenylation signal
  • FIG. 3 shows pancreatic islets of mDG770 transgenic mice with ectopic mDG770 expression.
  • beta-cell regeneration refers to an at least partial restoration of normal beta-cell function by increasing the number of functional insulin secreting beta-cells and/or by restoring normal function in functionally impaired beta-cells.
  • neurturin product includes neurturin protein products such as purified natural or synthetic neurturin and variants thereof. Variants include insertion, substitution and deletion variants and chemically modified derivatives. Variants also include recombinant proteins, for example but not limited to hybrids of neurturin and other TGF-beta proteins (preferably from the GDNF-family). Also included are proteins or peptides substantially homologous to the human neurturin precursor protein having the amino acid sequence published as GenBank Accession Number NP — 004549. The term “neurturin product” also includes polynucleotides (e.g. mRNA/DNA) encoding the above described neurturin protein product. The term “neurturin product” also includes neurturin homodimers or heterodimers of a neurturin protein product and another protein, wherein the other protein preferably belongs to the GDNF-family.
  • biologically active means that the neurturin product induces and/or stimulates the differentiation of insulin producing cells from progenitor, e.g. stem cells and/or promotes the protection, survival, or regeneration of insulin producing cells, e.g. beta-cells.
  • the biological activity of neurturin products may be determined as described in the Examples of the present application.
  • substantially homologous means having a degree of homology to the biologically active human neurturin product resulting from the cleavage of the neurturin precursor having the amino acid sequence published as GenBank Accession Number NP — 004549 or to the human neurturin precursor itself, that is preferably in excess of 70%, most preferably in excess of 80%, and even more preferably in excess of 90% or 95%.
  • the degree of homology between the mouse and the human protein is about 91%, and it is contemplated that preferred mammalian neurturin proteins will have a similarly high degree of homology.
  • proteins which are hybrids between neurturin and another TGFbeta-protein preferably another member of the GDNF-family which retain the stimulatory effect on islet cell formation found in Neurturin.
  • the percentage of homology or identity between a neurturin product and the human neurturin protein or a precursor or a nucleic acid coding therefor may be determined according to standard procedures, e.g. by using the BLAST algorithm.
  • the percentage of homology or identity is calculated as the percentage of nucleotide or amino acid residues found in the smaller of the two sequences that align with identical nucleotides or amino acid residues in the sequence being compared, when four gaps in a length of 100 nucleotides or amino acids may be introduced to assist in that alignment.
  • substantially homologous any neurturin protein product which may be isolated by virtue of cross-reactivity with antibodies to the neurturin protein product or whose genes may be isolated through hybridization with the gene or with segments of the gene encoding the neurturin protein product.
  • progenitor cells relates to undifferentiated cells capable of being differentiated into insulin producing cells.
  • the term particularly includes stem cells, i.e. undifferentiated or immature embryonic, adult, or somatic cells that can give rise to various specialized cell types.
  • stem cells can include embryonic stem cells (ES) and primordial germ cells (EG) cells of mammalian, e.g. human or animal origin. Isolation and culture of such cells is well known to those skilled in the art (see, for example, Thomson et al., 1998, Science 282:1145-1147; Shamblott et al., 1998, Proc. Natl. Acad. Sci. USA 95:13726-13731; U.S.
  • Embryonic stem cells can be isolated from the inner cell mass of pre-implantation embryos (ES cells) or from the primordial germ cells found in the genital ridges of post-implanted embryos (EG cells). When grown in special culture conditions such as spinner culture or hanging drops, both ES and EG cells aggregate to form embryoid bodies (EB). EBs are composed of various cell types similar to those present during embryogenesis. When cultured in appropriate media, EB can be used to generate in vitro differentiated phenotypes, such as extraembryonic endoderm, hematopoietic cells, neurons, cardiomyocytes, skeletal muscle cells, and vascular cells.
  • the term ‘cultivation medium’ means a suitable medium capable of supporting growth and differentiation of stem cells.
  • the term ‘differentiation medium’ means a suitable medium for inducing the differentiation of stem cells into insulin-producing cells.
  • the term ‘terminal differentiation medium’ means a suitable medium for terminal differentiation of insulin-producing cells. Examples of preferred media are described in WO/023018, which are herein incorporated by reference.
  • the neurotrophic factor neurturin to stimulate and/or induce the formation or regeneration of insulin producing cells and thus, a use in the treatment and prevention of diseases going along with (e.g. caused by, associated with or accompanied by) impaired beta-cell function, for example but not limited to diabetes mellitus. More particularly, the diseases are diabetes type I, diabetes type II or LADA.
  • the present invention is based on the surprising finding that neurturin stimulates the differentiation of insulin producing cells from stem cells in vitro.
  • a therapeutically effective amount of neurturin product may be administered to promote the regeneration of pancreatic beta-cells or to promote the formation of insulin-producing cells from stem cells or progenitor cells in vitro or in vivo.
  • the present invention further relates to applications in the medical field that directly arise from the method of the invention. Additionally, the present invention relates to applications for the identification and characterization of compounds with therapeutic medical effects or toxicological effects that directly arise from the method of the invention.
  • the neurturin product may be administered
  • neurturin expression level in a patient might be influenced by a neurturin modulator/effector administered
  • the neurturin product or the neurturin modulator/effector i.e. a pharmaceutically active substance influencing, particularly increasing the neurturin expression level or function may be administered in the above described manner alone or in combination with another pharmaceutical composition useful to treat beta-cell degeneration, for example hormones, growth factors or immune modulating agents.
  • a neurturin product or a modulator/effector thereof may be administered in patients suffering from a disease going along with impaired beta-cell function, for example but not limited to diabetes type I, LADA, or progressed diabetes type II. It is further contemplated that a neurturin product or the modulator/effector thereof may be administered preventively to patients at risk to develop beta-cell degeneration, like for example but not limited to patients suffering from diabetes type II or LADA in early stages. A variety of pharmaceutical formulations and different delivery techniques are described in further detail below.
  • the present invention also relates to methods for differentiating progenitor cells into insulin-producing cells in vitro comprising
  • pancreatic genes may comprise transfection of a cell with pancreatic gene operatively linked to an expression control sequence, e.g. on a suitable transfection vector, as described in WO 03/023018, which is herein incorporated by reference.
  • suitable transfection vector e.g. on a suitable transfection vector, as described in WO 03/023018, which is herein incorporated by reference.
  • pancreatic genes are Pdx1, Pax4, Pax6, neurogenin 3 (ngn3), Nkx 6.1, Nkx 6.2, Nkx 2.2, HB 9, BETA2/Neuro D, IsI 1, HNF1-alpha, HNF1-beta and HNF3 of human or animal origin.
  • Each gene can be used individually or in combination with at least one other gene.
  • Pax4 is especially preferred.
  • Neurturin products e.g. neurturin protein or nucleic acid products
  • Neurturin products are preferably produced via recombinant techniques because such methods are capable of achieving high amounts of protein at a great purity, but are not limited to products expressed in bacterial, plant, mammalian, or insect cell systems.
  • Recombinant neurturin protein product forms include glycosylated and non-glycosylated forms of the protein.
  • recombinant techniques involve isolating the genes encoding for neurturin protein product, cloning the gene in suitable vectors and/or cell types, modifying the gene if necessary to encode a desired variant, and expressing the gene in order to produce the neurturin protein product.
  • a nucleotide sequence encoding the desired neurturin product may be chemically synthesized. It is contemplated that a neurturin product may be expressed using nucleotide sequences that vary in codon usage due to the degeneration of the genetic code or allelic variations or alterations made to facilitate production of the protein product by the selected cell.
  • neurturin products may be isolated or generated by a variety of means. Exemplary methods for producing neurturin products useful are described in patent application WO 97/08196, the disclosures of which are hereby incorporated by reference. Also described are a variety of vectors, host cells, and culture growth conditions for the expression of neurturin protein, as well as methods to synthesize variants of neurturin protein product. Additional vectors suitable for the expression of neurturin protein product in E. coli are disclosed in Patent No. EP 0 423 980, the disclosure of which is hereby incorporated by reference.
  • the molecular weight of purified neurturin indicates that in its biologically active form the protein is a disulfide-bonded dimer.
  • the material isolated after expression in a bacterial system is essentially biologically inactive, and exists as a monomer. Refolding is necessary to produce the biologically active disulfide-bonded dimer. Processes suitable for the refolding and maturation of the neurturin expressed in bacterial systems are substantially similar to those described in WO93/06116. Standard in vitro assays for the determination of neurturin activity are also substantially similar to those determining GDNF activity as described in WO93/06116 and in U.S. application Ser. No. 08/535,681, and are hereby incorporated by reference.
  • Neurturin product variants are prepared by introducing appropriate nucleotide changes into the DNA encoding the polypeptide or by in vitro chemical synthesis of the desired polypeptide. It will be appreciated by those skilled in the art that many combinations of deletions, insertions, and substitutions can be made resulting in a protein product variant presenting neurturin biological activity.
  • Neurturin substitution variants have at least one amino acid residue of the human or mouse neurturin amino acid sequence removed and a different is residue inserted in its place.
  • substitution variants include allelic variants, which are characterized by naturally occurring nucleotide sequence changes in the species population that may or may not result in an amino acid change.
  • Chemically modified derivatives of neurturin protein products also may be prepared by one of skill in the art given the disclosures herein.
  • the chemical moieties most suitable for derivatization include water soluble polymers.
  • a water soluble polymer is desirable because the protein to which it is attached does not precipitate in an aqueous environment, such as a physiological environment.
  • the polymer will be pharmaceutically acceptable for the preparation of a therapeutic product or composition.
  • One skilled in the art will be able to select the desired polymer based on such considerations as whether the polymer/protein conjugate will be used therapeutically, and if so, the desired dosage, circulation time, resistance to proteolysis, and other considerations.
  • a particularly preferred water-soluble polymer for use herein is polyethylene glycol. Attachment at residues important for receptor binding should be avoided if receptor binding is desired.
  • the present invention contemplates use of derivatives which are prokaryote-expressed neurturin, or variants thereof, linked to at least one polyethylene glycol molecule, as well as use of neurturin, or variants thereof, attached to one or more polyethylene glycol molecules via an acyl or alkyl linkage.
  • Pegylation may be carried out by any of the pegylation reactions known in the art. See, for example: Focus on Growth Factors, 3 (2):4-10, 1992; EP 0 154 316, the disclosure of which is hereby incorporated by reference; EP 0 401 384; and the other publications cited herein that relate to pegylation.
  • the present invention also discloses use of derivatives which are prokaryote-expressed neurturin, or variants thereof, linked to at least one hydrophobic residue, for example fatty acid molecule, as well as use of neurturin, or variants thereof, attached to one or more hydrophobic residues.
  • neurturin or variants thereof
  • patent application published as WO 03/010185 describes a method for producing acylated polypeptides in transformed host cells by expressing a precursor molecule of the desired polypeptide which are then to be acylated in a subsequent in vitro step.
  • the present invention further provides polynucleotides that encode neurturin protein products, whether recombinantly produced or naturally occurring.
  • a nucleic acid sequence encoding a neurturin protein product can readily be obtained in a variety of ways, including, without limitation, chemical synthesis, cDNA or genomic library screening, expression library screening, and/or PCR amplification of cDNA. These methods and others useful for isolating such nucleic acid sequences are set forth, for example, by Sambrook et al. (Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989), by Ausubel et al., eds (Current Protocols in Molecular Biology, Current Protocols Press, 1994), and by Berger and Kimmel (Methods in Enzymology: Guide to Molecular Cloning Techniques, vol.
  • neurturin product polynucleotides with the native signal sequence and other pre-pro sequences as well as polynucleotides wherein the native signal sequence is deleted and replaced with a heterologous signal sequence.
  • the heterologous signal sequence selected should be one that is recognized and processed, i.e., cleaved by a signal peptidase, by the host cell.
  • the signal sequence is substituted by a prokaryotic signal sequence selected, for example, from the group of the alkaline phosphatase, penicillinase, or heat-stable enterotoxin 11 leaders.
  • the native neurturin signal sequence may be substituted by the yeast invertase, alpha factor, or acid phosphatase leaders.
  • the native signal sequence is satisfactory, although other mammalian signal sequences may be suitable.
  • Expression and cloning vectors generally include a nucleic acid sequence that enables the vector to replicate in one or more selected host cells.
  • Neurturin product pharmaceutical compositions typically include a therapeutically effective amount of a neurturin product in admixture with one or more pharmaceutically and physiologically acceptable formulation.
  • neurturin product pharmaceutical compositions may contain suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries, which facilitate processing of the active compounds into preparations, which can be used pharmaceutically. Further details on techniques for formulation and administration may be found in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing Co., Easton, Pa.), the disclosure of which is hereby incorporated by reference.
  • the therapeutic composition may be stored in sterile vials as a solution, suspension, gel, emulsion, solid, or dehydrated or lyophilized powder.
  • Such formulations may be stored either in a ready to use form or in a form, e.g., lyophilized, requiring reconstitution prior to administration.
  • the optimal pharmaceutical formulations will be determined by one skilled in the art depending upon considerations such as the route of administration and desired dosage. Such formulations may influence the physical state, stability, rate of in vivo release, and rate of in vivo clearance of the present neurturin proteins, variants and derivatives.
  • Other effective administration forms, such as slow-release formulations, inhalant mists, or orally active formulations are also envisioned.
  • the neurturin product may be bound to or incorporated into particulate preparations of polymeric compounds (such as polylactic acid, polyglycolic acid, etc.) or liposomes.
  • polymeric compounds such as polylactic acid, polyglycolic acid, etc.
  • the neurturin product may be administered by any suitable means, preferably enterally or parenterally or topically directly to the pancreas, as known to those skilled in the art.
  • the specific dose may be calculated according to considerations of body weight, body surface area or organ size. Further refinement of the calculations necessary to determine the appropriate dosage for treatment involving each of the above mentioned formulations is routinely made by those of ordinary skill in the art and is within the ambit of tasks routinely performed. Appropriate dosages may be ascertained through use of the established assays for determining dosages utilized in conjunction with appropriate dose-response data.
  • the final dosage regimen involved in a method for treating the above described conditions will be determined by the attending physician, considering various factors which modify the action of drugs, e.g., the age, condition, body weight, sex and diet of the patient, the severity of any infection, time of administration and other clinical factors. As studies are conducted, further information will emerge regarding the appropriate dosage levels for the treatment of various diseases and conditions.
  • neurturin protein products include proteins derivatized or otherwise formulated to effectuate such continuous administration.
  • Neurturin product cell therapy i.e. pancreatic implantation of cells producing neurturin protein product
  • This embodiment would involve implanting cells capable of synthesizing and secreting a biologically active form of neurturin protein product into patients.
  • neurturin protein product-producing cells may be cells that are natural producers of neurturin protein product or may be cells that are modified to express the protein.
  • modified cells include recombinant cells whose ability to produce a neurturin protein product has been augmented by transformation with a gene encoding the desired neurturin protein product in a vector suitable for promoting its expression and secretion.
  • the cells producing neurturin protein product be of human origin and produce human neurturin protein product.
  • the recombinant cells producing neurturin protein product be transformed with an expression vector containing a gene encoding a human neurturin protein product.
  • Implanted cells may be encapsulated to avoid infiltration of surrounding tissue.
  • Human or nonhuman animal cells may be implanted in patients in biocompatible, semipermeable polymeric enclosures or membranes that allow release of neurturin protein product, but that prevent destruction of the cells by the patient's immune system or by other detrimental factors from the surrounding tissue.
  • neurturin protein product secreting cells may be introduced into a patient in need intraportally via a percutaneous transhepatic approach using local anaesthesia. Between 3000 and 100 000 equivalent differentiated insulin-producing cells per kilogram body weight are preferably administered.
  • Such surgical techniques are well known in the art and can be applied without any undue experimentation, see Pyzdrowski et al, 1992, New England J. Medicine 327:220-226; Hering et al., Transplantation Proc. 26:570-571, 1993; Shapiro et al., New England J. Medicine 343:230-238, 2000.
  • neurturin protein product can be delivered directly to progenitor, e.g. stem cells in order to stimulate the differentiation of insulin producing cells.
  • progenitor e.g. stem cells
  • protein delivery can be achieved by polycationic liposomes (Sells et al. (1995) Biotechniques 19:72-76), Tat-mediated protein transduction (Fawell et al. (1993) Proc. Natl. Acad. Sci. USA 91:664-668) and by fusing a protein to the cell permeable motif derived from the PreS2-domain of the hepatitis-B virus (Oess and Hildt (2000) Gene Ther. 7:750-758).
  • neurturin may be added preferably at concentrations between 1 ng/ml and 500 ng/ml, more preferably between 10 and 100 ng/ml, e.g. at about 50 ng/ml.
  • the invention relates to a cell preparation comprising differentiated progenitor cells, e.g. stem cells exhibiting insulin production, particularly an insulin-producing cell line obtainable by the method described above.
  • the insulin-producing cells may exhibit a stable or a transient expression of at least one pancreatic gene involved in beta-cell differentiation.
  • the cells are preferably human cells that are derived from human stem cells. For therapeutic applications the production of autologous human cells from adult stem cells of a patient is especially preferred. However, the insulin producing cells may also be derived from non-autologous cells. If necessary, undesired immune reactions may be avoided by encapsulation, immunosuppression and/or modulation or due to non-immunogenic properties of the cells.
  • the insulin producing cells of the invention preferably exhibit characteristics that closely resemble naturally occurring beta-cells. Further, the cells of the invention preferably are capable of a quick response to glucose. After addition of 27.7 mM glucose, the insulin production is enhanced by a factor of at least 2, preferably by a factor of at least 3. Further, the cells of the invention are capable of normalizing blood glucose levels after transplantation into mice.
  • the invention further encompasses functional pancreatic cells obtainable or obtained by the method according to the invention.
  • the cells are preferably of mammalian, e.g. human origin.
  • said cells are pancreatic beta-cells, e.g. mature pancreatic beta-cells or stem cells differentiated into pancreatic beta-cells.
  • pancreatic beta cells preferably secrete insulin in response to glucose.
  • the present invention provides functional pancreatic cell that express glucagon in response to glucose.
  • a preparation comprising the cells of the invention may additionally contain cells with properties of other endocrine cell types such as alpha-cells, delta-cells and/or PP-cells. These cells are preferably human cells.
  • the cell preparation of the invention is preferably a pharmaceutical composition comprising the cells together with pharmacologically acceptable carriers, diluents and/or adjuvants.
  • the pharmaceutical composition is preferably used for the treatment or prevention of pancreatic diseases, e.g. diabetes.
  • the functional insulin producing cells treated with neurturin may be transplanted preferably intrahepatic, directly into the pancreas of an individual in need, or by other methods.
  • such cells may be enclosed into implantable capsules that can be introduced into the body of an individual, at any location, more preferably in the vicinity of the pancreas, or the bladder, or the liver, or under the skin.
  • Methods of introducing cells into individuals are well known to those of skill in the art and include, but are not limited to, injection, intravenous or parenteral administration. Single, multiple, continuous or intermittent administration can be effected.
  • the cells can be introduced into any of several different sites, including but not limited to the pancreas, the abdominal cavity, the kidney, the liver, the celiac artery, the portal vein or the spleen.
  • the cells may also be deposited in the pancreas of the individual.
  • gene therapy ex vivo i.e. the patient's own cells may be transformed ex vivo to produce a neurturin protein product or a protein stimulating neurturin expression and would be directly reimplanted.
  • cells retrieved from the patent may be cultured and transformed with an appropriate vector. After an optional propagation/expansion phase, the cells can be transplanted back into the same patient's body, particularly the pancreas, where they would produce and release the desired neurturin protein product. Delivery by transfection and by liposome injections may be achieved using methods, which are well known in the art. Any of the therapeutic methods described above may be applied to any suitable subject including, for example, mammals such as dogs, cats, cows, horses, rabbits, monkeys, and most preferably, humans.
  • Neurturin product gene therapy in vivo is also envisioned, by introducing the gene coding for a neurturin protein product into targeted pancreas cells via local injection of a nucleic acid construct or other appropriate delivery methods (Hefti, J. Neurobiol., 25:1418-1435, 1994).
  • a nucleic acid sequence encoding a neurturin protein product may be contained in an adeno-associated virus vector or adenovirus vector for delivery to the pancreas cells.
  • Alternative viral vectors include, but are not limited to, retrovirus, herpes simplex virus and papilloma virus vectors.
  • Physical transfer may also be achieved by liposome-mediated transfer, direct injection (naked DNA), receptor-mediated transfer (ligand-DNA complex), electroporation, calcium phosphate precipitation or microparticle bombardment (gene gun).
  • liposome-mediated transfer direct injection (naked DNA), receptor-mediated transfer (ligand-DNA complex), electroporation, calcium phosphate precipitation or microparticle bombardment (gene gun).
  • Immunosuppressive drugs such as cyclosporin
  • the neurturin nucleic acid and protein and effectors/modulators thereof may be administered either as a monotherapy or as a combination therapy with other pharmaceutical agents.
  • they may be administered together with other pharmaceutical agents suitable for the treatment or prevention of pancreatic diseases and/or obesity and/or metabolic syndrome, particularly with other pharmaceutical agents suitable for stimulating and/or inducing the differentiation of insulin producing cells from progenitor cells.
  • they may be administered together with pharmaceutical agents which have an immunosuppressive activity, e.g. antibodies, polypeptides and/or peptidic or non-peptidic low molecular weight substances.
  • immunosuppressive agents are listed in the following Table 1.
  • the combination therapy may comprise coadministration of the medicaments during the treatment period and/or separate administration of single medicaments during different time intervals in the treatment period.
  • a neurturin protein product and/or modulators/effectors thereof in a pharmaceutical composition leads to an at least partial regeneration of pancreatic cells.
  • these cells are insulin producing beta-cells that will contribute to the improvement of a diabetic state.
  • an increase in beta-cell mass can be achieved. This effect upon the body reverses the condition of diabetes partially or completely.
  • the dosage administered may be reduced in strength. In at least some cases further administration can be discontinued entirely and the subject continues to produce a normal amount of insulin without further treatment.
  • compositions of the present invention will also have efficacy for treatment of patients with other pancreatic diseases such as pancreatic cancer, dysplasia, or pancreatitis, if beta-cells are to be regenerated.
  • the present invention allows the production of cells for the identification and/or characterisation of compounds which stimulate beta-cell differentiation, insulin secretion and/or glucose response, more particularly of compounds which increase the neurturin expression level or function.
  • This method is particularly suitable for in vivo testing for diagnostic applications and drug development or screening.
  • the compound of interest is added to suitable cells and the neurturin expression or function is determined.
  • a compound of interest is added to a neurturin-treated cell and the effect on cell differentiation and/or insulin production is determined.
  • differentiated insulin-producing cells used. Insulin levels in treated cells can be determined, e.g. quantified by Enzyme Linked Immunoabsorbent Assay (ELISA) or Radio Immuno Assay (RIA).
  • ELISA Enzyme Linked Immunoabsorbent Assay
  • RIA Radio Immuno Assay
  • the cells are transfected with a DNA construct, e.g. a viral or non-viral vector containing a reporter gene, e.g. the lacZ gene or the GFP gene, under regulatory control of a promoter of a gene involved in beta-cell differentiation, e.g. preferably a Pax4 promoter.
  • a DNA construct e.g. a viral or non-viral vector containing a reporter gene, e.g. the lacZ gene or the GFP gene
  • a promoter of a gene involved in beta-cell differentiation e.g. preferably a Pax4 promoter.
  • the transfected cells are divided into aliquots and each aliquot is contacted with a test substance, e.g. candidate 1, candidate 2, and candidate 3.
  • the activity of the reporter gene corresponds to the capability of the test compound to induce beta-cell differentiation.
  • a medium throughput validation is carried out.
  • the test compound is added to cells being cultivated and the neurturin expression and/or the insulin production is determined.
  • an initial high throughput assay such as the cell based assay outlined above where e.g. a Pax4 promoter is used as marker for beta-cell regeneration
  • the activity of candidate molecules to induce beta-cell differentiation is tested in a validation assay comprising adding said compounds to the culture media of the embryoid bodies. Differentiation into insulin-producing cells is then evaluated, e.g. by comparison to wild type and/or Pax4 expressing cells to assess the effectiveness of a compound.
  • Mouse R1 ES cells (Nagy et al. (1993) Proc. Natl. Acad. Sci. USA. 90: 8424-8428) were electroporated with the Pax4 gene under the control of the CMV promoter and the neomycin resistance gene under the control of the phosphoglycerate kinase I promoter (pGK-1).
  • ES cells were cultured in Dulbecco's modified Eagle's medium containing 4.5 g/l glucose, 10 ⁇ 4 M beta-mercaptoethanol, 2 nM glutamine, 1% non-essential amino acids, 1 nM Na-pyruvate, 15% FCS and 500 U/ml leukaemia inhibitory factor (LIF). Briefly, approximately 10 7 ES cells resuspended in 0.8 ml phosphate buffered saline (PBS) were subjected to electroporation with 25 ⁇ g/ml of linearized expression vector (Joyner, Gene Targeting: A Practical Approach, Oxford University Press, New York, 1993).
  • PBS 0.8 ml phosphate buffered saline
  • ES cells Five minutes after electroporation, ES cells were plated on petri dishes containing fibroblastic feeder cells previously inactivated by treatment with 100 ⁇ g/ml mitomycin C. One day after electroporation, culture medium was changed to medium containing 450 ⁇ g/ml G418. Resistant clones were separately isolated and cultured 14 days after applying the selection medium. Cells were always cultured at 37° C., 5% CO 2 . These untreated and undifferentiated ES cells were used as control the experiment shown in FIG. 1 (referred to as ‘ES’ in FIG. 1 ).
  • the ES cell line R1 wild type, ‘wt ES’ in FIG. 1
  • ES cells constitutively expressing Pax4 ‘Pax4 ES’ in FIG. 1
  • EB embryoid bodies
  • EBs were plated separately onto gelatin-coated 6 cm cell culture dishes containing a differentiation medium prepared with a base of Iscove modified Dulbecco's medium. After dissociation and replating at day 14, cells were cultured up to 40 days in the differentiation medium prepared with a base of Dulbecco's modified Eagle medium: Nutrient Mixture F-12 (DMEM/F12).
  • DEM/F12 Nutrient Mixture F-12
  • pancreas specific genes was measured by semi-quantitative RT-PCR analysis. Differentiated wild type ES and Pax4 ES cells were collected after embryoid body formation and suspended in lysis buffer (4 M guanidinium thiocyanate, 25 mM sodium citrate, pH 7; 0.5% sarcosyl, 0.1 M beta-mercaptoethanol). Total RNA was isolated by the single step extraction method described by Chomczynski & Sacchi, 1987, Anal. Biochem. 162: 156-159).
  • mRNA was reverse transcribed using PolyT tail primer Oligo d(T) 16 (PerkinElmer) and the resulting cDNA was amplified using oligonucleotide primers complementary and identical to transcripts of beta-cell glucose transporter Glut2 and insulin.
  • the house keeping gene beta-tubulin was used as internal standard.
  • Reverse transcription (RT) was performed with MuLV reverse transcriptase (Perkin Elmer).
  • Multiplex PCRs were carried out using AmpliTaq DNA polymerase (Perkin Elmer) as described in Wobus at al., 1997, supra.
  • mRNA levels of genes encoding Glut2 and insulin were analysed using the Dynalbeads mRNA DIRECT micro kit (Dynal) according to the manufacturer's instructions.
  • Ethidium bromide fluorescence signals of gels were analyzed by a special software (TINA2.08e) The intensity of the ethidium bromide fluorescence signals was determined from the area under the curve for each peak and the data of target genes were plotted as percentage changes in relation to the expression of the housekeeping gene beta-tubulin.
  • Results show that markers for beta-cell differentiation function were expressed at higher levels in Pax4 + differentiated ES cells than in differentiated wild type ES cells demonstrating that activation of a pancreatic developmental control gene renders differentiation more efficient than for wild type ES cells ( FIG. 1 ).
  • Expression of Glut2 in differentiated stem cells indicates that hormone-producing cells are capable of responding to glucose.
  • Expression of substantial amounts of insulin in differentiated stem cells indicates that differentiated cells show a phenotype similar to beta-cells.
  • ES mouse embryonic stem
  • CMV cytomegalovirus
  • Embryoid bodies were formed in the presence of 50 ng/ml of neurturin solution in PBS-01% BSA. Embryoid bodies were subsequently plated, again neurturin was added every second day until day 12 and afterwards enzymatically dissociated, and replated.
  • neurturin was obtained from RDI Research Diagnostics INC, USA, Order Number RDI-4511. Under such conditions, the expression of insulin was significantly induced by neurturin in two independent examples ( FIGS. 1A and 1B ). In addition, the addition of neurturin to the differentiation medium did significantly enhance the expression of the glucose transporter Glut-2 in two independent examples ( FIGS. 1C and 1D ). By comparison, wild type ES cells did not contain any insulin-producing cell at the same stage and only small numbers of Glut-2 expressing cells. These data demonstrate that neurturin can significantly promote and enhance ES cells differentiation into insulin-producing cells compared to wild type ES cells.
  • FIG. 1 clearly demonstrate a significant induction of the differentiation of insulin-producing ( FIGS. 1A and 1B ) and glucose responsive ( FIGS. 1C and 1D ) cells, if neurturin is added to embryoid bodies.
  • neurturin has a strong inductive effect on the differentiation of insulin-producing beta cells.
  • beta-cells glucose responsive insulin secretion.
  • an in vitro glucose responsive assay was performed on the differentiated cells. On the day of the assay, the differentiation medium of 12 or 6 well plate was removed and the cells were washed 3 times with Krebs Ringer Bicarbonate Hepes Buffer (KRBH; 125 mM NaCl, 4.7 mM KCl, 1 mM CaCl 2 , 1.2 mM KH 2 PO 4 , 1.2 mM MgSO 4 , 5 mM NaHCO 3 , 25 mM Hepes, 0.1% BSA) supplemented with 2.8 mM glucose.
  • KRBH Krebs Ringer Bicarbonate Hepes Buffer
  • Insulin levels were determined by an Enzyme-Linked Immunosorbent Assay (ELISA) for mouse insulin (Mercodia) and performed according to the manufacture r's recommendations.
  • An alternative medium for proper insulin release was medium based on DMEM with glucose concentration of 1 g/l (Gibco) supplemented with non-essential amino acids (Gibco, stock solution 1:100) and additional factors mentioned above. Such medium can be applied 1 to 6 days before use of the cells.
  • a basal insulin secretion is expected when both wild type and neurturin induced insulin-producing cells are cultured in low glucose concentrations (2.8 mM). However, the neurturin induced insulin-producing cells highly respond to glucose simulation. In the presence of high glucose concentrations (16.7 mM), an increase in insulin secretion is expected in neurturin ES derived insulin-producing cells.
  • Streptozotocin is an antibiotic which is cytotoxic to beta-cells when administered at certain dosage (see Rodrigues et al.: Streptozotocin-induced diabetes, in McNeill (ed) Experimental Models of Diabetes, CRC Press LLC, 1999). Its effect is rapid, rendering an animal severely diabetic within 48 hours.
  • Non-fasted Male BalbC mice were treated with STZ to develop hyperglycaemia after STZ treatment. Mice were considered diabetic if they had a blood glucose level above 10 mmol/l for more than 3 consecutive days.
  • Cells were transplanted under the kidney capsule and into the spleen of animals. The presence of the insulin-producing cells was confirmed by immunohistological analysis of the transplanted tissue. Results are expected to demonstrate that the transplanted cells can normalise blood glucose in diabetic animals.
  • Transgenic construct DNA was injected into C57/BL6 x CBA embryos (Harlan Winkelmann, Borchen, Germany) using standard techniques (see, for example, Brinster et al. (1985), Proc. Natl. Acad. Sci. USA 82: 4438-4442).
  • the mDG770 transgene was expressed under the control of the rat insulin promoter II (Lomedico et al., supra) using techniques known to those skilled in the art (for example, see, Gunnig et al. (1987), Proc. Natl. Acad. Sci. USA 84, 4831-4835). Using this technique, several independent founderlines were generated.
  • Genotyping was performed by PCR using genomic DNA isolated from the tail tip.
  • a transgene specific forward primer (5′ tgc tat ctg tct gga tgt gcc 3′
  • a mDG770 transgene specific reverse primer (5′ aag gac acc tcg tcc tca tag 3′) was used.
  • mDG770 transgene in islets was monitored by TaqMan analysis.
  • 25 ng cDNA derived from pancreatic islet RNA isolated from transgenic mice and their littermates and a mDG770 specific primer/probe pair were used to detect endogenous as well as transgenic mDG770 expression (mDG770-1 forward primer: 5′ GCC TAT GAG GAC GAG GTG TCC 3′, mDG770 reverse primer: 5′ AGC TCT TGC AGC GTG TGG T 3′, mDG770 probe: 5′ TCC TGG ACG TGC ACA GCC GC 3′).
  • TaqMan analysis was performed using standard techniques known to those skilled in the art.
  • Ectopic transgene expression was detected in 3 of 4 rIP-mDG770 transgenic founderlines analysed. The two founderlines showing highest transgene expression levels were used for further analysis. For the level of mDG70 expression in islets of a transgenic animal compared to a wild-type animal, see also FIG. 3 .
  • mice 3 to 6 mice were housed per cage and were provided with food ad libitum. Metabolic blood parameters were determined using venous blood isolated from tail vein or via retroorbital bleeding. Blood glucose values were determined using One Touch blood glucose meters (LifeScan, Germany). mDG770 transgenic mice exhibit reduced random fed blood glucose levels (rIP-mDG770), compared to wild type (wt) mice, see also FIG. 4 .
US10/580,601 2003-11-27 2004-11-29 Method for Preventing and Treating Diabetes Using Neurturin Abandoned US20080241106A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US13/028,181 US8399408B2 (en) 2003-11-27 2011-02-15 Method for treating diabetes using neurturin
US13/769,011 US8772233B2 (en) 2003-11-27 2013-02-15 Method for promoting regeneration of pancreatic beta-cells by administering neurturin
US14/287,863 US20140274897A1 (en) 2003-11-27 2014-05-27 Method for preventing and treating diabetes using neurturin

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03027383.3 2003-11-27
EP03027383 2003-11-27
PCT/EP2004/013534 WO2005051415A1 (en) 2003-11-27 2004-11-29 Method for preventing and treating diabetes using neurturin

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/013534 A-371-Of-International WO2005051415A1 (en) 2003-11-27 2004-11-29 Method for preventing and treating diabetes using neurturin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/028,181 Continuation US8399408B2 (en) 2003-11-27 2011-02-15 Method for treating diabetes using neurturin

Publications (1)

Publication Number Publication Date
US20080241106A1 true US20080241106A1 (en) 2008-10-02

Family

ID=34626383

Family Applications (4)

Application Number Title Priority Date Filing Date
US10/580,601 Abandoned US20080241106A1 (en) 2003-11-27 2004-11-29 Method for Preventing and Treating Diabetes Using Neurturin
US13/028,181 Expired - Fee Related US8399408B2 (en) 2003-11-27 2011-02-15 Method for treating diabetes using neurturin
US13/769,011 Expired - Fee Related US8772233B2 (en) 2003-11-27 2013-02-15 Method for promoting regeneration of pancreatic beta-cells by administering neurturin
US14/287,863 Abandoned US20140274897A1 (en) 2003-11-27 2014-05-27 Method for preventing and treating diabetes using neurturin

Family Applications After (3)

Application Number Title Priority Date Filing Date
US13/028,181 Expired - Fee Related US8399408B2 (en) 2003-11-27 2011-02-15 Method for treating diabetes using neurturin
US13/769,011 Expired - Fee Related US8772233B2 (en) 2003-11-27 2013-02-15 Method for promoting regeneration of pancreatic beta-cells by administering neurturin
US14/287,863 Abandoned US20140274897A1 (en) 2003-11-27 2014-05-27 Method for preventing and treating diabetes using neurturin

Country Status (9)

Country Link
US (4) US20080241106A1 (pl)
EP (1) EP1694354B1 (pl)
JP (5) JP4838724B2 (pl)
AT (1) ATE435026T1 (pl)
DE (1) DE602004021847D1 (pl)
DK (1) DK1694354T3 (pl)
ES (1) ES2329583T3 (pl)
PL (1) PL1694354T3 (pl)
WO (1) WO2005051415A1 (pl)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110003741A1 (en) * 2007-11-05 2011-01-06 Develogen Aktiengesellschaft Novel neurturin conjugates for pharmaceutical use
US8399408B2 (en) 2003-11-27 2013-03-19 Develogen Aktiengesellschaft Method for treating diabetes using neurturin
WO2014138725A1 (en) * 2013-03-08 2014-09-12 Curators Of The University Of Missouri Methods and compositions for the treatment and/or prevention of type 1 diabetes
US9049849B2 (en) 2001-09-17 2015-06-09 Evotec International Gmbh Screening methods for compounds useful for treating pancreatic dysfunction
US20150190467A1 (en) * 2012-06-28 2015-07-09 Instituto De Medicina Molecular The use of ret agonist molecules for haematopoietic stem cell expansion protocols and transplantation therapy and a ret agonist kit

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1872790A1 (en) 2006-06-26 2008-01-02 DeveloGen Aktiengesellschaft New formulation for increasing bioavailability of neurturin
US8637459B2 (en) * 2006-11-08 2014-01-28 Emory University Enhancing a population of insulin releasing cells using GFR-A1 agonists
JP2011057674A (ja) 2009-09-11 2011-03-24 Omnica Gmbh コエンザイムｑ−１０と抗酸化剤とを含む組成物
CA2778678A1 (en) * 2009-10-30 2011-05-05 Cns Therapeutics, Inc. Improved neurturin molecules
US8445432B2 (en) 2009-10-30 2013-05-21 Ntf Therapeutics Inc Neurturin molecules
US9127083B2 (en) 2009-10-30 2015-09-08 Ntf Therapeutics, Inc. Neurturin molecules
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
US9617517B2 (en) 2011-05-02 2017-04-11 National University Corporation Kumamoto University Small chemical compound which promotes induction of differentiation of stem cells into insulin-producing cells and method for inducing differentiation of stem cells into insulin-producing cells using said small chemical compound
WO2013063389A2 (en) * 2011-10-26 2013-05-02 University Of Louisville Research Foundation, Inc. Methods and compositions for treating diabetes and other degenerative neuroendocrine diseases or disorders
KR20170086659A (ko) 2014-12-03 2017-07-26 벨리셉트 테라퓨틱스, 인크. 하부 요로 증상을 위한 변형 방출형 솔라베그론을 이용한 조성물 및 방법
FI3365321T3 (fi) 2015-10-23 2024-01-02 B3Ar Therapeutics Inc Solabegron-Zwitterioni ja sen käyttöjä
JP6960106B2 (ja) * 2018-01-17 2021-11-05 Toto株式会社 浴槽用枕
WO2020243419A1 (en) * 2019-05-30 2020-12-03 Immunolux International Corp. Use of poxvirus with autologous induced pluripotent stem cells for vaccination and disease therapy
CA3206590A1 (en) * 2021-01-30 2022-08-04 Maria Fatima Bosch Tubert Gene therapy for monogenic diabetes

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739307A (en) * 1995-08-28 1998-04-14 Washington University Polynucleotide encoding neurturin neurotrophic factor
US20050054102A1 (en) * 2001-04-19 2005-03-10 Anna Wobus Method for differentiating stem cells into insulin-producing cells

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6743628B1 (en) 1995-08-28 2004-06-01 Washington University Method of cell culture using neurturin
NZ336865A (en) 1997-01-23 2001-01-26 Sumitomo Pharma Use of a therapeutic agent containing a neurotrophic factor for treatment of diabetes and hyperlipemia
ATE312915T1 (de) * 1997-02-18 2005-12-15 Genentech Inc Neurturin-rezeptor
US6043221A (en) 1997-07-30 2000-03-28 Amgen Inc. Method for preventing and treating hearing loss using a neuturin protein product
EP1115866A1 (en) 1998-09-22 2001-07-18 University of Maryland at Baltimore Cystine knot growth factor mutants
WO2000018922A2 (en) 1998-10-01 2000-04-06 Incyte Genomics, Inc. Human carbohydrate-associated proteins
DK1223966T3 (da) 1999-10-29 2003-08-18 Bioph Biotech Entw Pharm Gmbh Anvendelse af GDNF til behandling af hornhindedefekter
AU3087801A (en) 2000-02-04 2001-08-14 Molecular Dynamics Inc Human genome-derived single exon nucleic acid probes useful for analysis of geneexpression in human breast and hbl 100 cells
US20050222070A1 (en) 2002-05-29 2005-10-06 Develogen Aktiengesellschaft Fuer Entwicklungsbiologische Forschung Pancreas-specific proteins
EP1507553A2 (en) 2002-05-29 2005-02-23 DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung Pancreas-specific proteins
WO2004093804A2 (en) 2003-04-18 2004-11-04 Five Prime Therapeutics, Inc. Human polypeptides encoded by polynucleotides and methods of their use
WO2005051415A1 (en) * 2003-11-27 2005-06-09 Develogen Aktiengesellschaft Method for preventing and treating diabetes using neurturin
EP1872790A1 (en) 2006-06-26 2008-01-02 DeveloGen Aktiengesellschaft New formulation for increasing bioavailability of neurturin
KR20150139982A (ko) 2007-11-05 2015-12-14 데벨로겐 악틴게젤샤프트 제약학적으로 용도되는 신규한 뉴트린 접합체

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739307A (en) * 1995-08-28 1998-04-14 Washington University Polynucleotide encoding neurturin neurotrophic factor
US20050054102A1 (en) * 2001-04-19 2005-03-10 Anna Wobus Method for differentiating stem cells into insulin-producing cells

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9049849B2 (en) 2001-09-17 2015-06-09 Evotec International Gmbh Screening methods for compounds useful for treating pancreatic dysfunction
US8399408B2 (en) 2003-11-27 2013-03-19 Develogen Aktiengesellschaft Method for treating diabetes using neurturin
US8772233B2 (en) 2003-11-27 2014-07-08 Evotec International Gmbh Method for promoting regeneration of pancreatic beta-cells by administering neurturin
US20110003741A1 (en) * 2007-11-05 2011-01-06 Develogen Aktiengesellschaft Novel neurturin conjugates for pharmaceutical use
US9029323B2 (en) 2007-11-05 2015-05-12 Evotec International Gmbh Neurturin conjugates for pharmaceutical use
US20150190467A1 (en) * 2012-06-28 2015-07-09 Instituto De Medicina Molecular The use of ret agonist molecules for haematopoietic stem cell expansion protocols and transplantation therapy and a ret agonist kit
US9821026B2 (en) * 2012-06-28 2017-11-21 Instituto De Medicina Molecular Use of RET agonist molecules for haematopoietic stem cell expansion protocols and transplantation therapy and a RET agonist kit
WO2014138725A1 (en) * 2013-03-08 2014-09-12 Curators Of The University Of Missouri Methods and compositions for the treatment and/or prevention of type 1 diabetes
CN105358678A (zh) * 2013-03-08 2016-02-24 密苏里大学董事会 治疗和/或预防1型糖尿病的方法和组合物
US11338036B2 (en) 2013-03-08 2022-05-24 The Curators Of The University Of Missouri Methods and compositions for the treatment and/or prevention of type 1 diabetes

Also Published As

Publication number Publication date
WO2005051415A1 (en) 2005-06-09
US8772233B2 (en) 2014-07-08
JP2011251986A (ja) 2011-12-15
JP2007512290A (ja) 2007-05-17
EP1694354B1 (en) 2009-07-01
EP1694354A1 (en) 2006-08-30
US20130150293A1 (en) 2013-06-13
US20140274897A1 (en) 2014-09-18
JP2016000759A (ja) 2016-01-07
ES2329583T3 (es) 2009-11-27
US8399408B2 (en) 2013-03-19
JP2012001546A (ja) 2012-01-05
US20110256113A1 (en) 2011-10-20
DK1694354T3 (da) 2009-10-26
DE602004021847D1 (de) 2009-08-13
JP5647577B2 (ja) 2015-01-07
JP2014074066A (ja) 2014-04-24
ATE435026T1 (de) 2009-07-15
JP4838724B2 (ja) 2011-12-14
PL1694354T3 (pl) 2009-12-31

Similar Documents

Publication Publication Date Title
US8772233B2 (en) Method for promoting regeneration of pancreatic beta-cells by administering neurturin
WO2006013114A1 (en) Use of a timp-2 secreted protein product for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
US20080207594A1 (en) Use of Gsk-3 Inhibitors for Preventing and Treating Pancreatic Autoimmune Disorders
JP2004511209A (ja) 細胞の脱分化及び組織の再生のための組成物及び方法
CA2485216A1 (en) Therapeutic use of pacap, maxadilan, pacap receptor agonist and/or adcyap1r1 in the treatment of cns disorders
JP5122973B2 (ja) Ｅｓ細胞からすい臓を生産する方法
JP2021521895A (ja) 哺乳動物細胞における組織再生の誘導及びセノリシスのための改良された方法
US20090298771A1 (en) Use of secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
WO2006136374A2 (en) Use of gip and/or vitamin d3 analogues thereof for enhancing stem or progenitor cell differentiation into insulin producing cells
Moro et al. Analysis of beta cell proliferation dynamics in zebrafish
US20070110728A1 (en) Method for preventing and treating diabetes using dg119
US8481486B2 (en) Methods of treating neurological diseases by regulating migration of neuroblasts in the adult nervous system with tenascin-R
EP1605965B1 (en) Use of saposin-related proteins for preventing and treating obesity, diabetes and/or metabolic syndrome
WO2006108651A2 (en) Use of activin products for preventing and treating diabetes and/or metabolic syndrome
US8501473B2 (en) Use of pleitrophin for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
JP2023515915A (ja) 腸のニューロパチーを治療するためのグリア細胞株由来神経栄養因子（ｇｄｎｆ）の使用
US20070050856A1 (en) Use of protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
US20070107073A1 (en) Use of secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome

Legal Events

Date Code Title Description
AS Assignment

Owner name: DEVELOGEN AKTIENGESELLSCHAFT, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:AUSTEN, MATTHIAS;BURK, ULRIKE;REEL/FRAME:017960/0459

Effective date: 20060307

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION